Secondary Acute Myeloid Leukemia — Trials

Secondary Acute Myeloid Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

212 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 46
Recruiting: 21
Ph III recruiting: 0
Growth YoY: —
Industry share: 7%
Top sponsor: National Cancer Institute (NCI)
Termination share: 31.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (39)

clinicaltrialsPublishedShowing 1–21 of 21 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05780879	A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia	terminated	Phase 2	10	University of Michigan Rogel Cancer CenterOTHER	1	Aug 24, 2026	clinicaltrials
NCT03146871	Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent	terminated	Phase 2	7	University of Southern California